VEGF-C treatment, while not impacting the percentage of Tregs, increased the ratio of CD8+Ki67+T cells to Tregs in both CLNs and tumor sites, indicating an enhancement of immune microenvironment [31]. The gene discussed is VEGFC; the disease is neoplasm.